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Tuberculosis is still one of the most important health problems in the world. In developed countries, the proportion of
extrapulmonary tuberculosis cases is increasing. Nowadays tuberculous spondylitis, also known as Pott disease, is a rare clinical
condition but can cause severe vertebral and neurological sequelae that can be prevented with an early correct diagnosis. 'e aim
of this paper is to increase awareness of tuberculous spondylitis inmodern times, describing three di1erent cases and discussing its
best diagnostic and therapeutic approach based on the current literature.
1. Introduction
In 2014, among all 6 million noti3ed cases of tuberculosis
(TB), 0.8 million (14%) were new cases of extrapulmonary
tuberculosis [1]. Tuberculous spondylitis, also called Pott
disease, accounts for 1–5% of TB cases and represents about
50% of all bone and joint TB [2]. Despite the successful
achievement in decreasing global pulmonary TB incidence
in the last decades, the proportion of extrapulmonary
tuberculosis seems to be increasing in developed countries,
mainly as a consequence of higher immigration rates and
human immunode3ciency virus (HIV) infection [3]. Despite
all technological advances, the diagnosis of tuberculous
spondylitis remains a clinical challenge since it depends on
a high grade of clinical suspicion. Notwithstanding the low
reported mortality of tuberculous spondylitis, this condi-
tion is still associated with signi3cant clinical morbidity. In
particular, signi3cant diagnostic delay may lead to severe
skeletal deformities and irreversible neurological compli-
cations [4].
'e purpose of this paper is to describe three cases of
tuberculous spondylitis, focusing the diagnostic and treat-
ment options according to the current literature.
2. Case Reports
2.1. Case 1. A 37-year-old Portuguese man, heavy smoker,
with a history of alcohol and drug abuse, and concomitant
HIV infection (CD4+T cell count 360 cells/μL) under highly
active antiretroviral therapy since 1998, was currently med-
icated with efavirenz, emtricitabine, and tenofovir. One year
before presentation, he had a TB contact and was not screened
for active or latent TB infection. He was admitted due to
a two-month history of severe back pain, with no constitu-
tional or respiratory symptoms and no neurological signs.
Magnetic resonance imaging (MRI) of the spine revealed
peripheral lesions located at T9-T10 vertebral bodies, asso-
ciated with discreet compression of spinal cord, small para-
vertebral abscess, and empyema. A percutaneous biopsy
was performed. 'e microscopy smear of the acid-fast bacilli
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(AFB), the nucleic acid ampli3cation test (NAAT), and the
culture of Mycobacterium tuberculosis (MT) were positive,
with no drugs resistance. 'e patient was started on isoniazid
(H), rifampin (R), pyrazinamide (Z), and ethambutol (E)
(HRZE) for 4 months, due to slow radiological resolution of
the vertebral lesions, and remained in therapy with HR for
2 years. He currently has no symptoms or signi3cant vertebral
sequelae.
2.2. Case 2. A 60-year-old Portuguese woman, nonsmoker,
HIV negative, with a history of vertebral decompression
surgery due to a herniated disc 8 years before, presented with
severe back pain lasting 18 months and left lower limb
paresthesia, with no fever or respiratory symptoms. MRI of
the spine showed central lesions at bodies of L2 and L3,
intervertebral foramen reduction, and compression of the L3
spinal root, as well as an epidural abscess (white arrow in
Figure 1). 'e patient had surgery with 3xation and ar-
throdesis of the segments involved. Surgical biopsy revealed
MT (NAAT and culture positive; no drug resistance). 'e
patient was treated with 2 months of HRZE and then HR
until 1 year. She has now chronic back pain controlled
with medication, no neurological impairment, or signi3cant
kyphotic deformity.
2.3. Case 3. A 23-year-old Portuguese man, smoker, HIV
negative, with recentmultidrug-resistant tuberculosis (MDR-TB)
contact, presented with acute lower back pain with radi-
ation to the right Jank. 'ere were no respiratory, con-
stitutional, or neurological symptoms. Abdominal computerized
tomography (TC) showed a retroperitoneal perirenal abscess.
Empiric antibiotic treatment and surgical drainage were
performed. After 4 months of persistent symptoms, a MRI
of the spine was done, which showed instability of the spine
due to total lytic bone destruction of T11 and T12 vertebral
bodies, focal lytic lesions at bodies T5-T10 bodies, peri-
vertebral abscesses, and also a psoas abscess. A percutaneous
biopsy revealed MT (AFB and culture positive). Molecular
testing for drug resistance was positive to isoniazid and ri-
fampicin. No other resistance was observed in culture with
drug sensibility tests. Other organ involvement was excluded.
Surgical stabilization with an autograph reconstruction of T11
and T12 was performed. 'e patient started an anti-MDR TB
therapy with pyrazinamide, ethambutol, amikacin, levoJoxacin,
ethionamide, and cycloserine. He 3nished treatment after two
years. He has now a moderate chronic back pain and vertebral
body loss although with no kyphotic deformity.
3. Discussion
'ree distinct scenarios of tuberculous spondylitis were de-
scribed, enhancing di1erent clinical characteristics, treatment
approaches, and outcomes.
Commonly, in tuberculous spondylitis, the symptoms
develop insidiously due to the slow progression of the
disease, contributing to a signi3cant delay between symp-
toms onset and diagnosis. Even in developed countries, as we
observed in the cases described, time to diagnosis can take
more than six months, and it represents one of the worst
prognostic factors [5]. Back pain is the most common
symptom (83–100% of the patients), and constitutional
symptoms, including fever, are relatively rare (33%) [3].
Spine deformities and neurological de3cits are the worst
complications of tuberculous spondylitis. Despite all the
advances in diagnostic techniques, in developed countries,
neurological de3cits are still present at the time of diagnosis
in 45% of the cases [6].
'e mean age of patients with tuberculous spondylitis is
45–60 years, although two peaks are reported concerning
risk factors: one between 20 and 30 years, related to im-
migration and HIV, and one between 60 and 70 years, re-
lated to immunosuppression and comorbidities [5]. In case
2, the older age and the inexistence of constitutional
symptoms or major risk factors may have contributed to the
longer delay in the diagnosis. In these situations, other more
frequent diagnoses of chronic back pain are usually con-
sidered, such as degenerative joint disease. In the other hand,
cases with more acute onset of the symptoms may raise the
hypothesis of pyogenic infection [7] In cases 1 and 3, pa-
tients were young and had associated major risk factors
(HIV and previous TB/MDR-TB contact), which made the
hypothesis of TB infection more likely.
Commonly, tuberculous spondylitis a1ects the thoracic
and thoracolumbar segments with initial destruction of the
vertebral bodies. Other segments and multifocal in-
volvement are uncommon [5]. Concomitant paraspinal
abscesses and epidural involvement can be seen, respec-
tively, in around 70% and 65% of the cases. As in the cases
described, a signi3cant percentage of patients do not show
evidence of the primary infection focus. Concurrent pul-
monary involvement can range from 2 to 65% [3].
Diagnostic suspicion of tuberculous spondylitis is based
on clinical and radiological features. Spinal radiography may
show a destructive process of vertebras and adjacent discs if
osteomyelitis is present. 'ese 3ndings only appear in a late
course of the disease and are less pronounced compared to
Figure 1: Case 2: sagittal T2-weighted image showing lytic lesions
at L2 and L3 vertebral bodies, intervertebral disc destruction,
anterior epidural abscess (white arrow), and scoliotic deformity
centered in L2-L3.
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pyogenic infection. Nowadays, highly sensitive and speci3c
techniques are available that can overcome these limitations.
Spinal CT and MRI can achieve the same diagnostic yield [5].
'e CT helps to de3ne the extent of the disease and is the
best method to detect calci3ed foci, characteristic in tu-
berculous infections and rare in pyogenic infections. Spinal
MRI is more sensitive in early stages of the disease since it
provides better tissue contrast than CT and permits a better
visualization of the epidural space and spinal cord. 'e
overall sensitivity and speci3city of MRI for tuberculous
spondylitis is 100% and 80%, respectively, which renders the
MRI the best radiological method for the diagnosis of tu-
berculous spondylitis [8]. MRI is also helpful to clarify the
need for surgical intervention, since it is the most precise
radiological method to assess nervous system involvement
and spine instability.
Although clinical and radiological 3ndings can be sug-
gestive of tuberculous spondylitis, biopsy—either open biopsy
or CT-guided percutaneous aspiration biopsy (PAB)—should
be performed in order to obtain a de3nitive diagnosis. PAB
has a low morbidity associated and a diagnostic yield of 68%,
which makes it the method of choice in patients with no
indication to surgery [9]. 'e tuberculin skin test (TST) and
interferon-gamma release assays (IGRAs) are not routinely
used in the diagnosis of extrapulmonary TB since they cannot
di1erentiate latent from active TB infection. However, in
diMcult cases, their high negative predictive value may be
helpful in rule out tuberculous spondylitis in the presence of
spinal osteomyelitis. When tuberculous spondylitis coexists
with other forms of TB, if MT is already documented in
other specimen and typical radiological features of tubercu-
lous spondylitis are present, we can assume the same etiology;
otherwise, MT should be isolated to con3rm the diagnosis.
Microbiological analyses can include acid-fast bacilli (AFB)
microscopy smear, the nucleic acid ampli3cation test
(NAAT), culture identi3cation of MT, and the drug sus-
ceptibility test (DST). Histological analysis should also be
performed since the presence of caseating granulomas can
support the diagnosis. 'e extrapulmonary samples (EPS) are
characteristically paucibacillary which diMcult the diagnosis.
Diagnostic sensitivity of AFB smear microscopy (Ziehl–
Neelsen and Juorescent staining) is low, although in some
studies it can be seen in up to 58% of the cases [9, 10].
Sensitivity of MTculture can be as high as 83% in solid media
(Lowenstein-Jensen), but the slow growing time of up to 3–8
weeks is a limitation [11]. Liquid media, such as Middlebrook
media, have been developed in order to reduce the mean time
of culture (2-3 weeks) and also show higher sensitivity [9].MT
culture is necessary for an accurate DST in order to obtain the
best therapeutic regimen. Despite the fact that paucibacillar
forms and NAAT inhibitors contribute to false negative
results, several studies show that NAAT can be successfully
tested in EPS, achieving a sensitivity of 72% [12]. 'is
method can reduce the diagnosis time to hours, and
therefore, it is also helpful to readily di1erentiate between
MT and no MT infection. However, international guide-
lines still only recommend this test in respiratory speci-
mens. In case 1, positive AFB microscopy smear and NAAT
allowed to make an early de3nitive diagnosis of tuberculous
spondylodiscitis. In case 2, a negative AFB and positive NAAT
made the diagnosis of MT infection more likely, avoiding
a delay in the initiation of anti-TB therapy. More recently,
new molecular methods are available for MT identi3cation
and drug susceptibility testing. 'e Xpert MTB/RIF assay has
a sensitivity and speci3city of 81% and 99%, respectively, in
extrapulmonary TB diagnosis and can simultaneously access
the resistance to rifampicin within two hours [13]. Speci3cally
in bone and joint TB, the Xpert MTB/RIF assay demonstrated
a sensibility of 82% and speci3city of 100% in the diagnosis
and a 100% concordance with culture-DSTfor the detection of
RIF resistance [14]. 'is assay was endorsed for extrap-
ulmonary TB diagnosis by the WHO in 2013 [15]. Other tests
such as the GenoType MTBDRplus (MTBDR) assay, which
detects both rifampicin and isoniazid resistances, have been
also studied, showing sensitivity of 72% in bone and joint TB,
although more data are needed [14]. 'ese molecular tests
provide a rapid access to results and consequently an early
correct 3rst-line treatment. In cases of suspected MDR, as
case 3, Xpert should be performed.
'e goal of tuberculous spondylitis treatment is not only
to eradicate infection but also to treat and prevent neuro-
logical complications and spinal deformities. Pharmaco-
logical treatment should be initiated as soon as the diagnosis
is con3rmed, with 2 months of HRZE (intensive phase)
followed by 4 to 7 months of HR (continuation phase). 'e
duration of treatment remains controversial. Due to diM-
culties in assessing response and risk of relapse, most experts
recommend 9 to 12 months of treatment, and in situations
of slow radiological resolution as case 2, 12 to 24 months of
treatment should be considered [16–18]. 'e hypothesis of
MDR must always be taken into account, and a de3nitive
anti-TB regimen should be based on susceptibility tests.
MDR is usually a result of inappropriate drug therapy and is
rarely innate [19]. In case 3, his previous contact raised the
possibility of a MDR-TB, and thus the anti-TB regimen was
based on susceptibility test of the contact patient. Directly
observed treatment (DOT) is recommended in order to
ensure treatment adherence. Corticosteroid therapy is not
recommended in cases of tuberculous spondylitis unless
there is meningeal involvement. Surgery is con3ned to
patients that present with neurological de3cits caused by
spinal cord compression, spinal deformity with instability,
severe or progressive kyphosis, large paraspinal abscesses,
and no response or failure of anti-TB therapy [6]. As de-
scribed, both cases 2 and 3 had clear indication for surgery.
In contrast, the clinical and radiological features of case 1
were indicative for conservative treatment. Conservative
treatment is considered in cases with mild to moderate
neurologic de3cits, mild vertebral body involvement (one
central lesion or various peripheral lesions in up to 3 ver-
tebral bodies) and canal involvement, mild paravertebral
abscess, no retropharyngeal or psoas abscess, and no sig-
ni3cant kyphosis (less than 30°) or intervertebral instability
[18]. 'e need for surgery is directly related to the diagnostic
delay, and it is seen in more than 50% of the cases [20].
Indication for surgery also depends on available local re-
sources and surgical expertise. 'e pharmacological and
surgical treatments, when necessary, are e1ective and have
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a low relapse rate (0–5%). Studies in the last decade showed
a mortality rate of 4% [3].
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